MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414796 | Name: Pazufloxacin Free Base
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pazufloxacin Free Base is a fluoroquinolone antibiotic and potent DNA gyrase inhibitor.

Chemical Structure

Pazufloxacin Free Base
Pazufloxacin Free Base
CAS#127045-41-4 (free base)

Theoretical Analysis

MedKoo Cat#: 414796

Name: Pazufloxacin Free Base

CAS#: 127045-41-4 (free base)

Chemical Formula: C16H15FN2O4

Exact Mass: 318.1016

Molecular Weight: 318.30

Elemental Analysis: C, 60.37; H, 4.75; F, 5.97; N, 8.80; O, 20.11

Price and Availability

Size Price Availability Quantity
25mg USD 400.00 2 Weeks
100mg USD 700.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
163680-77-1 (mesylate) 127045-41-4 (free base)
Synonym
Pazufloxacin Free Base; CCRIS 7312; CCRIS7312; CCRIS-7312; T 3761; T3761; T-3761
IUPAC/Chemical Name
(-)-(3S)-10-(1-Aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
InChi Key
XAGMUUZPGZWTRP-ZETCQYMHSA-N
InChi Code
InChI=1S/C16H15FN2O4/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22/h4-5,7H,2-3,6,18H2,1H3,(H,21,22)/t7-/m0/s1
SMILES Code
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(C4(N)CC4)C(F)=CC1=C23)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 318.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kai M, Tanaka R, Suzuki Y, Goto K, Ohchi Y, Yasuda N, Tatsuta R, Kitano T, Itoh H. UHPLC-MS/MS method for simultaneous quantification of doripenem, meropenem, ciprofloxacin, levofloxacin, pazufloxacin, linezolid, and tedizolid in filtrate during continuous renal replacement therapy. J Clin Lab Anal. 2023 Jan;37(1):e24815. doi: 10.1002/jcla.24815. Epub 2022 Dec 16. PMID: 36525363; PMCID: PMC9833962. 2: Umezaki Y, Matsumoto K, Ikawa K, Yokoyama Y, Enoki Y, Shigemi A, Watanabe E, Nakamura K, Ueno K, Terazono H, Morikawa N, Takeda Y. Concentration-Dependent Activity of Pazufloxacin against Pseudomonas aeruginosa: An In Vivo Pharmacokinetic/Pharmacodynamic Study. Antibiotics (Basel). 2022 Jul 21;11(7):982. doi: 10.3390/antibiotics11070982. PMID: 35884236; PMCID: PMC9312304. 3: Qi J, Yang X, Pan PY, Huang T, Yang X, Wang CC, Liu W. Interface Engineering of Co(OH)2 Nanosheets Growing on the KNbO3 Perovskite Based on Electronic Structure Modulation for Enhanced Peroxymonosulfate Activation. Environ Sci Technol. 2022 Apr 19;56(8):5200-5212. doi: 10.1021/acs.est.1c08806. Epub 2022 Apr 8. PMID: 35394751. 4: Asai Y, Yamamoto T, Abe Y. Evaluation of the Expression Profile of Antibiotic-Induced Thrombocytopenia Using the Japanese Adverse Drug Event Report Database. Int J Toxicol. 2021 Dec;40(6):542-550. doi: 10.1177/10915818211048151. Epub 2021 Oct 18. PMID: 34658275. 5: Nagata J, Kawasaki T, Iesato K, Sugiura T, Yamauchi K, Tsuyusaki J, Fujimura M, Kuroda F, Mikami K, Dudek SM, Tanabe N. A Case of Candidemia after Long-term Presence of Urethral Foreign Bodies. IDCases. 2021 Jun 8;25:e01176. doi: 10.1016/j.idcr.2021.e01176. PMID: 34159054; PMCID: PMC8196048. 6: Kai M, Tanaka R, Suzuki Y, Goto K, Ohchi Y, Yasuda N, Tatsuta R, Kitano T, Itoh H. Simultaneous quantification of plasma levels of 12 antimicrobial agents including carbapenem, anti-methicillin-resistant Staphylococcus aureus agent, quinolone and azole used in intensive care unit using UHPLC-MS/MS method. Clin Biochem. 2021 Apr;90:40-49. doi: 10.1016/j.clinbiochem.2021.01.012. Epub 2021 Feb 2. PMID: 33539809. 7: Ren Z, Wang Y, Xu H, Li Y, Han S. Fuzzy Comprehensive Evaluation Assistant 3D-QSAR of Environmentally Friendly FQs to Reduce ADRs. Int J Environ Res Public Health. 2019 Aug 29;16(17):3161. doi: 10.3390/ijerph16173161. PMID: 31470687; PMCID: PMC6747076. 8: Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056. J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):76. doi: 10.1089/jop.2017.0056.correx. Erratum for: J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. PMID: 30699060; PMCID: PMC6354593. 9: Niu H, Yee R, Cui P, Zhang S, Tian L, Shi W, Sullivan D, Zhu B, Zhang W, Zhang Y. Identification and Ranking of Clinical Compounds with Activity Against Log-phase Growing Uropathogenic Escherichia coli. Curr Drug Discov Technol. 2020;17(2):191-196. doi: 10.2174/1570163815666180808115501. PMID: 30088449. 10: Ando M, Masuda T, Yamasue M, Nureki SI, Miyazaki E, Kadota JI. A case of maoto-induced interstitial pneumonia. J Thorac Dis. 2018 Jun;10(6):E485-E489. doi: 10.21037/jtd.2018.05.82. PMID: 30069411; PMCID: PMC6051839. 11: Huang Q, Wei W, Wang L, Chen H, Li T, Zhu X, Wu Y. Synthesis of uniform Ag nanosponges and its SERS application. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Aug 5;201:300-305. doi: 10.1016/j.saa.2018.05.019. Epub 2018 May 9. PMID: 29763823. 12: Huang ZX, Zeng ZB, Xu ZP. [Purtscher-like retinopathy associated with antibiotic anaphylaxis]. Nan Fang Yi Ke Da Xue Xue Bao. 2018 Mar 20;38(3):239-242. doi: 10.3969/j.issn.1673-4254.2018.03.01. PMID: 29643027; PMCID: PMC6744167. 13: Baiza-Durán L, Olvera-Montaño O, Mercado-Sesma AR, Oregon-Miranda AA, Lizárraga-Corona A, Ochoa-Tabares JC, Pérez-Balbuena AL, Montoya-Sánchez IM, Saucedo-Rodríguez LR, Mora-González A, Gómez-Bastar PA, Villanueva-Najera MA, Sandoval-Delgadillo LI, González-Lomelí M, Páez-Garza JH, Orozco-Carroll M, Casillas-Magallanes M. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. J Ocul Pharmacol Ther. 2018 Apr;34(3):250-255. doi: 10.1089/jop.2017.0056. Epub 2018 Jan 11. Erratum in: J Ocul Pharmacol Ther. 2019 Jan/Feb;35(1):76. doi: 10.1089/jop.2017.0056.correx. PMID: 29624493. 14: Miyashita N, Kobayashi I, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kurachi S, Ishikawa T, Ishimura Y, Kanesaka I, Kiyota H, Watanabe A. In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan. J Infect Chemother. 2018 May;24(5):325-329. doi: 10.1016/j.jiac.2018.01.018. Epub 2018 Feb 17. PMID: 29459000. 15: Khan AM, Rampal S, Sood NK. Effect of levofloxacin, pazufloxacin, enrofloxacin, and meloxicam on the immunolocalization of ABCG-2 transporter protein in rabbit retina. Environ Sci Pollut Res Int. 2018 Mar;25(9):8853-8860. doi: 10.1007/s11356-018-1216-y. Epub 2018 Jan 12. PMID: 29330817. 16: Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H, Watanabe A. Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy. J Infect Chemother. 2017 Nov;23(11):727-732. doi: 10.1016/j.jiac.2017.09.001. Epub 2017 Sep 23. PMID: 28951197. 17: Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, Morinaga S, Kajikawa K, Kato Y, Watanabe M, Zennami K, Kanao K, Morikawa N, Sumitomo M. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis. J Infect Chemother. 2017 Dec;23(12):809-813. doi: 10.1016/j.jiac.2017.08.005. Epub 2017 Oct 12. PMID: 28923301. 18: Hamasuna R, Ohnishi M, Matsumoto M, Okumura R, Unemo M, Matsumoto T. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates. Microb Drug Resist. 2018 Jan/Feb;24(1):30-34. doi: 10.1089/mdr.2017.0054. Epub 2017 Jun 5. PMID: 28581359. 19: Yamasaki K, Yatera K, Kato K, Noguchi S, Kawanami T, Fukuda K, Naito K, Akata K, Ishimoto H, Taniguchi H, Mukae H. Successful Additional Corticosteroid Treatment in a Patient with Mycoplasma pneumoniae Pneumonia in whom a Monobacterial Infection was Confirmed by a Molecular Method Using Bronchoalveolar Lavage Fluid. Intern Med. 2016;55(6):703-7. doi: 10.2169/internalmedicine.55.5124. Epub 2016 Mar 15. PMID: 26984095. 20: Chen J, Lu N, Shen X, Tang Q, Zhang C, Xu J, Sun Y, Huang XA, Xu Z, Lei H. Investigation of an Immunoassay with Broad Specificity to Quinolone Drugs by Genetic Algorithm with Linear Assignment of Hypermolecular Alignment of Data Sets and Advanced Quantitative Structure-Activity Relationship Analysis. J Agric Food Chem. 2016 Apr 6;64(13):2772-9. doi: 10.1021/acs.jafc.6b00039. Epub 2016 Mar 28. PMID: 26982746.